So both Sprott and Hartley's have taken a conservative approach with their $1.05 & $1.15 valuation factoring in a less favorable scoping study (0.5x NAV) which avoids potential market disappointment, but opens the door to substantial upside if the scoping study is positive.
None of this includes Jambi.
Scoping Study, page-2
Add CTM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.010(2.56%) |
Mkt cap ! $197.9M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 40.0¢ | 38.0¢ | $790.9K | 1.998M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1320 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 12500 | 2 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
38.5¢ |
Change
0.010 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| 39.0¢ | 39.0¢ | 38.0¢ | 82177 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| CTM (ASX) Chart |